Corporate Banner
Satellite Banner
Technology Networks Header
Tuesday, October 21, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
New Test can Help Doctors Choose Best Treatment for Ovarian Cancer
ADNEX discriminate between benign and malignant tumours with a high level of accuracy.
All the Cell’s a Stage
Brian Strahl, PhD, and his band of biochemists unravel the complicated mysteries of the epigenetic code to find a culprit in cancer development.
New Cancer Drug To Begin Trials In Multiple Myeloma Patients
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.
ISB Gets $6.5 Million from NCI
Company has received two-year contract to create ‘Cancer Genomics Cloud’ with partners Google and SRA International.
Precise Control Over Genes Results from Game-Changing Research
UCSF invention greatly amplifies power of CRISPR technology.
Unusual Skin Cancer Linked To Chronic Allergy
Scientists have learned that inflammation at the site of an allergic skin rash can promote skin tumor formation if it persists.
New Clues For Early Colorectal Cancer Detection
Study identifies new biomarkers which could help detect colorectal cancer.
New 'Lab-on-a-Chip' Could Revolutionize Early Diagnosis of Cancer
Faster result times, reduced costs, minimal sample demands and better sensitivity of analysis.
Dramatic Response And Resistance To Cancer Drug Traced
Sequencing reveals why thyroid tumor responded to, and eventually resisted, treatment.
Personalized Ovarian Cancer Vaccines
UConn Researchers have found a new way to identify protein mutations in cancer cells.
Scroll Up
Scroll Down
Return
Efficient and Specific Quantification of Mammalian microRNAs by a Novel Real-Time PCR Approach
Eric Lader, Director, QIAGEN, speaking at the RNAi World Congress 2007
Date Posted: Wednesday, December 19, 2007
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



QIAGEN, AstraZeneca to Develop Liquid Biopsy-based Companion Diagnostic
The collaboration is to advance EGFR mutation profiling in lung cancer patients.
Monday, July 28, 2014
QIAGEN Licenses Blood Cancer Biomarkers
Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including NGS gene panels, for blood cancers.
Saturday, July 26, 2014
QIAGEN, Lilly form CDx Collaboration
Companies to co-develop companion diagnostics for simultaneous analysis of DNA and RNA biomarkers in common cancers.
Friday, May 30, 2014
QIAGEN Reports Fourth Quarter and Full-Year 2013 Results
Company reports adjusted net sales OF $1.31 billion for 2013 with growth in all regions and customer classes.
Thursday, January 30, 2014
QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Companion Diagnostics
Several lymphoma-related biomarkers, including EZH2 Y641 gene mutations, rights acquired from British Columbia Cancer Agency.
Monday, June 10, 2013
QIAGEN Achieves Milestone with U.S. Approval of Companion Diagnostic for Colorectal Cancer
U.S. launch of therascreen® KRAS RGQ PCR kit offers enhanced approach to guide treatments for approximately 110,000 patients annually in U.S. with colorectal cancer.
Wednesday, July 11, 2012
QIAGEN Expands Access to State-of-the-Art HPV Screening in China
Coinciding with International Women’s Day, QIAGEN also joins fifth year of campaign to provide free HPV testing to underprivileged women in China.
Thursday, March 08, 2012
QIAGEN to Acquire SABiosciences
Transaction adds to QIAGEN’s content engine for development of future diagnostics and boosts the Company’s presence in pharma discovery and validation.
Tuesday, November 10, 2009
Nobel Prize to HPV Researcher Highlights Importance of Cervical Cancer Screening and Prevention
The Nobel Prize-winning discovery of the causal link between human papillomavirus (HPV) and cervical cancer has spurred lifesaving prevention technologies – such as HPV testing and HPV vaccines - that are helping to eradicate cervical cancer globally.
Tuesday, October 07, 2008
Qiagen Forms a User Forum for High-Throughput RNAi Screening
The user forum aims to facilitate advances in RNAi screening in drug target identification and systems biology.
Tuesday, March 28, 2006
Qiagen Develops Leading Solutions for RNA Interference
Qiagen will develop world’s largest collection of validated siRNAs through an extensive validation project.
Tuesday, December 13, 2005
Qiagen Delivers the Human Druggable Genome siRNA Set
This second generation siRNA set enables gene silencing studies of 6992 potential human druggable targets.
Friday, September 30, 2005
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv